Abstract 316P
Background
Although Olaparib has demonstrated substantial clinical benefits as maintenance therapy in BRCA mutation-carrying women with newly diagnosed advanced ovarian cancer, its effectiveness in patients without BRCA mutations remains under-investigated. This study aims to provide the first evidence on the efficacy of olaparib maintenance therapy in such a context.
Methods
Using real-world data from eleven high-volume tertiary care centers in China, we conducted a retrospective cohort study to assess the efficacy and safety of olaparib maintenance therapy in BRCA wild-type ovarian cancer patients in the first-line setting. Eligible women were identified by medical record review at each institution. The primary objective was the 1-year progression-free survival (PFS) rate. Details of safety profile were also evaluated.
Results
A total of 50 patients with a median age of 54 years were included. Of these patients, 44 (88%) had International Federation of Gynaecology and Obstetrics (FIGO) stage III disease at diagnosis, while 6 (12%) had stage IV disease. The 1-year PFS rate was 75.2% (95% CI, 63.4 to 89.2) and the median PFS was 21.0 months (95% CI, 13.8 to 28.2). All patients received olaparib at a starting dose of 300 mg twice daily and no patients experienced serious adverse events (AEs). Eight (16%) patients had a dose adjustment, but no patients discontinued olaparib treatment due to AEs.
Conclusions
We provide the first evidence that olaparib could be a safe and effective first-line maintenance treatment for women with BRCA wild-type ovarian cancer. These findings propose a new treatment option for this sizable patient subgroup.
Clinical trial identification
NCT05153603.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AZ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract